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With over 25 years of experience as 
physician, teacher, researcher, speaker, and 
author, Dr. Robert A. Robinson has a very 
active role in the UI Department of 
Pathology, Carver College of Medicine, at 
the University of Iowa Hospitals and 
Clinics.   
Dr. Robinson received an M.D. from the 
University of Missouri-Kansas City, a 
Ph.D. from the University of Minnesota, 
and completed a Pathology Residency at 
Mayo Graduate School of Medicine. 
Dr. Robinson currently holds a faculty 
position as Professor of Pathology in the 
Carver College of Medicine and a 
secondary appointment in the Department 
of Oral Pathology, Radiology and Medicine 
in the University of Iowa College of 
Dentistry.  
Dr. Robinson practices general surgical 
pathology and cytology, but specializes in 
diseases of the head and neck. Dr. 
Robinson also serves as the Medical 
Director of UI Diagnostic Laboratories 
(UIDL) where he leads the growth and 
expansion of the department’s national 
reference laboratory outreach program. 
Dr. Robinson recently celebrated the 
completion of his first book entitled “Head 
and Neck Pathology:  Atlas for Histologic 
and Cytologic Diagnosis” which has been 
published and distributed by Lippincott 
Williams & Wilkins,   (JAMA Review:  
http://jama.ama-
assn.org/cgi/content/full/303/18/1867-a) 
Dr. Robinson has over 150 publications and 
has made numerous presentations at 
national CME meetings.  
He is an active member in multiple 
professional societies including the Iowa 
Association of Pathologists, CAP, ASCP, 
and USCAP, among others. Dr. Robinson 
was also nationally recognized for his 
expertise by "Best Doctors in America". 
2009-2010. 
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1. What are the most important 
goals of sampling a pulmonary mass 
via aspiration or exfoliative cytology 
techniques? 
The primary goal is to establish, with 
certainty, the biologic nature of the 
mass; benign (eg, inflammatory) 
versus malignant. If a lesion can be 
placed into the ‘‘malignant’’ category, 
then the second objective is to 
determine whether it is a primary or 
metastatic lesion. Ancillary studies, 
such as immunocytochemistry, can be 
very helpful in this regard, particularly 
when the clinical picture is unclear, 
and are worthwhile uses of residual 
material. When the lesion is a primary 
lung tumor, the distinction between 
small cell and nonsmall cell histology 
is important for proper classification. 
These diagnostic objectives have not 
changed despite the molecular-driven 
changes in pulmonary oncologic 
practice. 
2. What is the clinical significance of 
distinguishing NSCLC subtypes on 
cytologic specimens? 
The principal (albeit not sole) driver of 
the interest in specifying subtypes of 
NSCLC in pathology reports is the 
advent of bevacizumab (Avastin), a 
vascular endothelial growth factor 
(VEGF) receptor inhibitor, as a 
treatment of NSCLC. Briefly, 
bevacizumab was found to have an 
unacceptable risk of life-threatening 
pulmonary hemorrhage in patients 
Cancer Cytology  
December 23, 2010 
The recent accumulation of epidemiologic and molecular research focused on nonsmall cell lung cancer (NSCLC) in 
combination with the development of novel/targeted therapies has caused pathologists to critically evaluate the issue 
of the histologic subclassification of such tumors. The use of the generic term NSCLC, once fully endorsed and 
accepted by our oncology colleagues, has recently been taken to task, and we are being asked, ‘‘Can you tell if it is a 
squame or an adeno?” by our clinical partners on a routine basis. This shift in framework in the diagnostic reporting of 
lung cancer poses practical challenges in the arena of diagnostic pulmonary cytology. Although cytology is an 
excellent discriminator of small cell carcinoma versus nonsmall cell carcinoma, it is less reliable in the subclassification 
of NSCLC.1 Furthermore, we are being asked to provide molecular-level information on small biopsy specimens 
(epidermal growth factor receptor [EGFR] gene mutations, KRAS gene mutation, ALK-EML4 gene fusion, etc), which 
is even more problematic for many cytologic specimens (aspirates, brushes, washes) that may have very limited 
residual specimen for testing. How does all this impact the day-to-day sign out of pulmonary cytology specimens? A 
few points for consideration are presented below. The reader can draw his or her own conclusions, and we will 
welcome a spirited and critical debate in this journal. 
 
 
Commentary 
 
Neoplastic Pulmonary Cytology:  
Why All the Fuss Over ‘‘NSCLC’’? 
Michael B. Cohen, MD and Jamie A. Weydert, MD 
 
Michael B. Cohen 
Jamie A. Weydert 
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who have squamous cell (compared 
with nonsquamous cell) 
morphology. Data on bevacizumab 
were limited by the relatively small 
number of patients studied and by 
the lack of correlation to other 
nonhistologic factors (ie, tumor 
size, location).2 Nonetheless, 
pathologists have been tasked with 
trying to separate squamous and 
nonsquamous, ie, adenocarcinoma, 
histologies on biopsy and cytologic 
specimens. The use of ancillary 
studies, such as p63 (squamous cell 
marker) and TTF-1 (thyroid 
transcription factor 1, also known 
as NKX2-1, a marker of pulmonary 
adenocarcinoma) have been 
advocated by some as a surrogate 
for morphologic classification.3 
The key question becomes, 
‘‘Should limited material be 
sacrificed for this type of ancillary 
testing to determine eligibility for a 
single, expensive, treatment 
modality?’’ Perhaps this question is 
better addressed by asking another 
question, ‘‘Does a generic 
diagnosis of so called ‘NSCLC’ 
preclude the patient from being 
evaluated for surgical therapy, 
radiation therapy, or 
chemotherapy?’’ The answer, of 
course, is ‘‘no’’. The issue of ‘‘best 
use’’ of residual cytologic material 
is addressed in our final point of 
consideration below. 
3. What molecular information 
do oncologists need to treat 
advanced/metastatic NSCLC? 
Targeted therapy has emerged that 
can extend survival in patients with 
NSCLC, depending on the type of 
molecular abnormality within the 
tumor clone. Molecular testing for 
EGFR Her-1 mutations and/or 
 Targeted therapy 
has emerged that 
can extend survival 
in patients with 
NSCLC… 
Kirsten-ras (KRAS [rat sarcoma]) 
mutations is quickly becoming a 
practice standard, and testing for 
the anaplastic lymphoma receptor 
tyrosine kinase-Echinoderm 
microtubule-associated protein-like 
4 (ALK-EML4) gene fusion may be 
joining this list.4,5 Cytology 
specimens can be adequate for this 
type of testing, and this is an area of 
both challenge and opportunity for 
pathologists to enhance patient 
care. The challenge is to provide a 
means by which adequate material 
can be obtained for these important 
molecular studies. Possibilities 
include increased use of immediate 
specimen evaluation for adequacy 
by pathologists and the use of novel 
specimen-preservation 
techniques.3,6 One need only to 
examine the success of reflex 
human papilloma virus (HPV) 
testing in liquid-based collections 
in cervical-vaginal screening to see 
how alterations in cytologic 
methods can be used to enhance 
patient care in the setting of new 
epidemiologic and molecular 
knowledge of a common disease. 
Although EGFR and KRAS 
represent the ‘‘now’’ of molecular 
testing in NSCLC, the field of 
targeted therapy is rapidly evolving 
and, ideally, residual material in 
cytologic specimens will be 
available for future retrospective 
testing as new agents become 
available. 
In summary, it is our opinion that 
neoplastic pulmonary cytology 
maintains its role in medicine as a 
useful, sentinel, diagnostic method 
of documenting malignancy. The 
use of the generic term NSCLC, 
however, is increasingly being 
called into question. Although the 
diagnosis of NSCLC may be 
reasonable, pathologists are 
strongly encouraged to offer a more 
precise morphologic classification, 
if possible. Molecular testing 
should be performed on newly 
diagnosed NSCLC, and 
pathologists are well suited to 
provide guidance in optimizing 
cytologic material collection and 
preservation to meet these patients’ 
care needs. 
Cancer Cytopathol. 2011 Feb 25;119(1):3-
4. doi: 10.1002/cncy.20131. Epub 2010 
Dec 23. 
Neoplastic pulmonary cytology: Why All 
the Fuss Over "NSCLC"? 
Cohen MB, Weydert JA. 
Department of Pathology, University of 
Iowa, Iowa City, Iowa. michael-
cohen@uiowa.edu. 
PMID: 21319309 [PubMed - in process] 
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UIDL Corner 
NEW:  4th Generation HIV 
Antigen/Antibody (Ag/Ab) Combo 
  
The UIHC Core Clinical Chemistry 
Laboratory is now running the Abbott 
Diagnostics’ HIV Antigen/Antibody 
(Ag/Ab) Combo, an automated 
FDA-approved assay that detects 
both antigen and antibody in 
patients infected with either HIV-1 
(group M and O) or HIV-2.  For 
antigen detection, the assay uses 
monoclonal antibodies directed against 
a highly conserved p24 peptide 
sequence of HIV-1 and HIV-2. 
A positive Combo assay indicates 
either acute or chronic infection with 
HIV-1 and/or HIV-2.  Relative to other 
HIV screening tests such as ELISA or 
OraQuick that detect antibodies 
against the virus, the Combo assay 
shortens the “serological window”, 
reducing the chance of a false-
negative result in a patient who has 
not yet produced enough antibodies to 
be detected with ELISA or other tests 
for anti-HIV antibodies. 
The antigen-antibody combination 
tests are designated “fourth-
generation” HIV tests and have been 
available in Europe for nearly a 
decade, and are now considered 
standard of care in Great Britain, 
France, and Germany.  The Centers for 
Disease Control and Prevention (CDC) 
has actively worked since 2007 to 
encourage the marketing of fourth-
generation HIV tests in the United 
States. 
 
Like many other HIV screening tests 
(including ELISAs), the Combo assay 
is not approved for children less than 
two years old.  For HIV screening in 
children less than two years, PCR 
testing is often used.  Consultation 
with pediatric infectious disease 
specialists is recommended if unsure 
about testing approaches in children 
less than two years old.  
UIDL Test Directory:  HIV 
Antigen/Antibody Combo, Plasma 
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  NEW:  Lamellar Body Count 
(Fetal Lung Maturity) 
Effective Monday, October 25, 
2010, the UIHC Core Laboratory 
changed the main method used to 
assess fetal lung maturity by 
analysis of amniotic fluid.  The 
older, discontinued test was an 
Abbott Diagnostics assay that 
measures the surfactant/albumin 
ratio.  The new assay is 
“LAMELLAR BODY COUNT”, 
which measures 1-5 micron 
diameter partiles of surfactant 
(lamellar bodies) that increase 
throughout gestational age and 
correlate with lung maturity. The 
analysis of lamellar bodies will be 
done in the Hematology laboratory. 
 
For a reference range, each result 
will have appended a table relating 
percent risk of respiratory distress 
syndrome based on lamellar body 
count and gestational age (in 
weeks).  This table is based on a 
published study (Karcher R et al. 
Gestational age-specific predicted 
risk of neonatal respiratory distress 
syndrome using lamellar body 
count and surfactant-to-albumin 
ratio on amniotic fluid.  Am J 
Obstet Gynecol 193(5):1680-1684, 
2005). 
  
Like the surfactant/albumin ratio 
test, the lamellar body count cannot 
be performed with amniotic fluid 
contaminated with blood or 
meconium.   We will continue to 
offer the Phosphatidylglycerol (PG) 
assay on amniotic fluid, which can 
be used if the sample is 
contaminated with meconium or 
blood.  UIDL Test Directory:  
Lamellar Body Count 
 
NEW:  Ethylene Glycol 
Immunoassay, Human 
Specimens 
 
The UIHC Core Clinical Chemistry 
laboratory has introduced an 
immunoassay for Ethylene Glycol, 
the toxic component of most 
automobile antifreezes.  This new 
assay has a rapid turnaround time 
compared to the more labor-
intensive gas chromatography 
method.  There are two ways this 
assay will be performed: 
  
1. Following clinician order. 
  
2. Automatic reflex order when the 
“Ethanol Volatile Panel” is ordered 
and the unexplained osmolar gap 
(including correction for plasma 
ethanol, if present) is greater than 15. 
  
An ethylene glycol plasma 
concentration of 10 mg/dL or 
greater is considered a critical 
value and will be reported to the 
ordering clinician. 
  
Currently, the pathology resident 
on-call is notified when there is a 
high unexplained osmolar gap.  
With the introduction of the 
ethylene glycol immunoassay, the 
pathology resident will be 
contacted only if osmolar gap is 
still greater than 15 after 
determining the ethylene glycol 
plasma concentration and 
estimating the contribution of 
ethylene glycol to plasma 
osmolality. 
  
The ethylene glycol immunoassay 
will NOT detect methanol, 
isopropanol, or propylene glycol, 
which still require gas 
chromatography analysis for 
quantitation.  Toxicity by these 
other alcohols and glycols are not 
common, but do occur and can be 
clinically serious.  
  
Our retrospective analysis from 
1996-2010 revealed 10 confirmed 
methanol and 15 confirmed 
isopropanol ingestions at the 
University of Iowa Hospitals and 
Clinics (i.e., 1 or less per year).  If 
there is a persistent high 
unexplained osmolar gap and/or 
clinical suspicion of ingestion of 
methanol or isopropanol, the gas 
chromatography analysis can still 
be ordered after consultation with 
the pathology resident or 
attending.  
  
Other explanations for high 
unexplained osmolar gap include 
heavy ethanol ingestion (with 
ethanol metabolites and/or 
ketoacidosis), mannitol, activated 
charcoal, propylene glycol (often 
from intravenous medications such 
as lorazepam or diazepam), or 
contrast dye. 
  
We hope that the new ethylene 
glycol immunoassay will facilitate 
rapid diagnosis of ethylene glycol 
poisoning, which continues to be a 
persistent public health issue.  The 
availability of the ethylene glycol 
immunoassay will also allow for 
more frequent determinations of 
follow-up plasma concentrations (if 
clinically indicated) in patients 
undergoing therapy with the 
antidote fomepizole and/or 
hemodialysis.  UIDL Test 
Directory:  Ethylene Glycol, 
human specimen 
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NEW TEST:  Ethylene Glycol, 
Vet Specimens 
  
This assay is intended for 
measurement of ethylene glycol in 
plasma of animals under veterinary 
care. This procedure individually 
quantitates ethylene glycol by an 
enzymatic immunoassay using the 
enzyme glycerol dehydrogenase. 
  
Note: This procedure is not suitable for 
the detection of other toxic alcohols 
including methanol and isopropranol, or 
for detection of propylene glycol 
(commonly found as diluent in some 
intravenous medications). 
 
Ethylene glycol is commonly found in 
many automobile antifreezes. Ethylene 
glycol has a sweet taste.  Animals may 
ingest ethylene glycol that has spilled on 
the ground or from bottles of antifreeze 
that are not capped tightly.  Toxic 
concentrations of ethylene glycol in 
animals are not well defined, but 
ethylene glycol plasma concentrations of 
> 50 mg/dL in dogs and > 20 mg/dL in 
cats have been associated with severe 
toxicity from kidney failure or other 
organ damage if untreated. 
 
References: Incidence of ethylene glycol 
intoxication in dogs and cats seen at 
Colorado State University Veterinary 
Teaching Hospital. Vet Hum Toxicol 29: 
41-44, 1987. UIDL Test Directory:  
Ethylene Glycol, Vet 
 
NEW:  Respiratory Virus Panel 
PCR 
 
The UIHC Microbiology Laboratory 
now offers a Respiratory Virus Panel 
PCR assay (by nasopharyngeal 
swab) which tests for 8 respiratory 
viruses:  Influenza A (including 
H1N1), Influenza B, parainfluenza 
viruses 1, 2, 3, adenovirus, 
respiratory syncytial virus (RSV), 
and human metapneumovirus. 
  
Human metapneumovirus, discovered 
in 2001, is a respiratory virus related 
to RSV.  Its clinical manifestations are 
also similar to that of RSV and range 
from mild upper respiratory infections 
to bronchiolitis and severe 
pneumonia.The expected turnaround 
time is 1-2 days.  
  
For additional test information please 
call UIDL Client Services 1-866-844-
2522.  UIDL Test Directory: 
Respiratory Virus Panel PCR 
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 Contact us 
 
For additional consultation and 
testing information, please visit 
our website at 
www.healthcare.uiowa.edu/
uidl  
or call Client Services at  
1-866-844-2522. 
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New Faculty 
Dennis Firchau, MD 
Clinical Assistant Professor of Anatomic Pathology 
The UI Department of Pathology would like to announce the addition of Dr. Dennis Firchau, 
Clinical Assistant Professor of Anatomic Pathology, to the faculty team.  Dr. Firchau's clinical 
duties and interests include autopsy and forensic pathology, cardiovascular pathology and 
medical education.   
Dr. Firchau received an M.D. from Wayne State University School (2004), completed a 
Pathology Residency at the Medical College of Wisconsin (2008), a Cardiovascular Pathology 
Fellowship at Mayo Clinic (2009) and most recently completed a Forensic Pathology 
Fellowship at the Hennepin Medical Examiner’s Office (2010).   
 
Department News 
 
Dennis Firchau 
 
• NEW STAFF • APPOINTMENTS • RECOGNITIONS • 
Two UI pathologists appointed Deputy Medical 
Examiners for Johnson County  
Drs. Marcus Nashelsky and Dennis Firchau were recently appointed Deputy Medical 
Examiners of Johnson County.  They provide comprehensive forensic autopsy services to this 
county and, previously, provided much background support to the Johnson County Medical 
Examiner Department.  These appointments will formalize their role in the death investigation 
component of the ME Dept operations. 
Eleven UI Pathologists among 'Best Doctors in 
America' recognizes University of Iowa Pathologists 
The University of Iowa Department of Pathology is pleased to have 11 physicians recognized 
among the 2011-12 Best Doctors in America®.   
This year's list includes Jo Benda, Leslie Bruch, Michael Cohen, Laila Dahmoush, Barry 
De Young, Chris Jensen, Patricia Kirby, Frank Mitros, Steven Moore, Robert A. 
Robinson, and Nancy Rosenthal.  
Only about 5 percent of doctors practicing in the U.S. are selected for each Best Doctors list. 
The Best Doctors in America® database includes the names and professional profiles of more 
than 45,000 of the best doctors in the United States. An exhaustive peer review determines the 
physicians included in the database. Only those who earn the consensus support of their peers 
as well as meet additional qualification criteria are included. 
Marcus Nashelsky 
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Wellstone Muscular Dystrophy Center Awarded 
$7.8 Million Grant 
The Paul D. Wellstone Muscular Dystrophy Cooperative Research Center at The University of 
Iowa has received a five-year, $7.8 million grant renewal from the National Institute of 
Neurological Disorders and Stroke to advance its work on finding treatments for muscular 
dystrophies. 
The UI center, led by center director Kevin Campbell, PhD, professor and head of molecular 
physiology and biophysics, and a Howard Hughes Medical Institute investigator, was 
established in 2005. It brings together researchers and clinicians to translate laboratory 
discoveries into clinical applications to treat a group of congenital and limb girdle muscular 
dystrophies. The center also focuses on research training and education. 
In addition to Dr. Campbell, the UI team is led by center co-director Steven Moore, MD, PhD, 
professor of pathology, and Katherine Mathews, MD, director of pediatric neurology at UI 
Children’s Hospital.  The UI center is one of six around the country named after Sen. Paul D. 
Wellstone (D-Minn.) who died in 2002. As a senator, Wellstone was instrumental in passing 
legislation that mandates that the NIH establish centers of excellence for basic and clinical 
research into forms of muscular dystrophy. 
 
Awards and Recognition 
 
Dr. Nancy Rosenthal Named Assistant Dean for 
Student Affairs 
Nancy Rosenthal, MD, has been named as the new Assistant Dean for Student Affairs in 
the Carver College of Medicine. Dr. Rosenthal joined the College faculty in 1998 and was 
promoted to full Professor (Clinical) in 2003. During her tenure at the University of Iowa 
she has served as Director of the Hemostasis Laboratory, Director of the Hematopathology 
fellowship, and most recently as Vice Chair for Education for the Department of Pathology. 
She has taught for many years in several Pathology courses, was named the Walter Beirring 
Professor of Clinical Education by the College in 2007, and most recently, chaired one of the 
curriculum design committees. 
Steven Moore 
 
Nancy Rosenthal 
 
• GRANTS • CERTIFICATES • PROMOTIONS • REVIEWS • 
Dr. Mitros Awarded J.P. Long Teaching Award 
Congratulations to Frank Mitros, MD, who was recently honored at the 2011 Carver College 
of Medicine Faculty Awards Banquet. Dr. Mitros was the recipient of the John P. Long 
Teaching Award in Basic Sciences.  This award recognizes the outstanding career-level 
teaching contributions by a basic science faculty member. Frank Mitros 
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Robert A. Robinson 
 
Barry DeYoung 
 
Matthew Krasowki 
 
Chris Jensen 
 
Sergei Syrbu 
 
Kevin Legge 
 
2010-2011 Faculty Promotions 
The Department is pleased to congratulate the following faculty members on their recent 
promotions.  The promotions are effective for the 2010–11 academic year, beginning July 1.  
Thank you all for your continued dedication!  
Congratulations goes to Chris Jensen, MD, who has been promoted to Clinical Professor of 
Pathology, Sergei Syrbu, MD, who has been promoted to Clinical Associate Professor of 
Pathology, and Kevin Legge MD, who has been promoted to Associate Professor of Pathology. 
 
Dr. Robert A Robinson Named Vice Chair of 
External Affairs 
Robert A. Robinson, MD, has been named as the new Vice Chair of External Affairs for the 
Department of Pathology.  He has been recognized for the important role he has played as 
Medical Director of UI Diagnostic Laboratories (UIDL), and the success of the department’s 
Outreach Program.  As the Vice Chair for External Affairs his duties will focus on referring 
physician relations as well as alumni relations. 
Dr. Barry DeYoung Named Vice Chair of Faculty 
Affairs 
Barry DeYoung, MD, has been named as the new Vice Chair for Faculty Affairs.  In this role 
Dr. DeYoung will initially help with faculty recruitment and development, chair the Faculty 
Development Committee, and take the lead in overseeing the mentoring of the faculty. 
Dr. Matt Krasowski Named Assistant Director of 
Clinical Laboratories 
Matt Krasowki, MD, has been named as the new Assistant Director of Clinical Laboratories.  
He has played an increasingly important role in clinical affairs for the Hospital. 
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Dr. Fred Dee received an Innovation in Teaching with 
Technology Award from the University of Iowa Academic 
Technologies Advisory Council. The title of the project is 
Development and Assessment of a Web-based Student 
Generated Cause and Effect Diagrams in Science and 
Education. The amount of this award is $35,500.  
 
Dr. Hasem Habelhah received a notice of R01 funding 
from the National Institutes of Health. The title of this 
project is RIP1 Cleavage by Caspase-8 is Essential for 
TRAIL-induced NF-kB Activation. This award is for the 
period of February 23, 2010 through December 31, 2014. 
The amount of this award is $1,556,250.  
 
Dr. Siegfried Janz received notice of funding from the 
following: 
1) International Waldenstrom's Macroglobulinemia 
Foundation (IWMF) for a research project titled 
Development of a Transgenic Mouse Model of 
Waldenstrom's Macroglobulinemia. This award total is 
$540,000 and is for the period of August 1, 2010 through 
July 31, 2012. 
2) R01 funding from the National Institutes of Health. The 
title of the project is Defining Genetic Pathways of Plasma-
Cell Neopolasia. This award is for the period of July 19, 
2010 through May 31, 2015. The amount of this award is 
$1,564,377.  
3)  Holden Comprehensive Cancer Center, through the 
Cancer Center Designated Gift Fund. This funding is 
earmarked for collaborative multiple myeloma research. 
This collaboration includes Dr. Apolina Goel (Radiation 
Research Lab), Dr. Sarah Holstein (Internal Medicine) and 
Dr. Margarida Magalhaes-Silverman (Internal Medicine). 
This award is for $19,290.  
 
4) Myeloma Research Foundation (MMRF) for a research 
project titled Pre-clinical Validation of IL-6 for 
Translational Myeloma Research. This award total is 
$200,000 and is for the period of December 1, 2009 through 
November 30, 2011. 
 
Dr. C. Michael Knudson received a notice of funding from 
the Holden Comprehensive Cancer Center, through the 
Oberley Seed Grant Program. The title of this project is 
Developing Models to Address the Role of Oxidative Stress 
in Chromosome Instability and Cancer. This award is for 
the period of March 1, 2010 through February 28, 2011. 
The amount of this award is $50,000.  
 
Dr. Thomas Waldschmidt received a notice of NIH R01 
subcontract funding from Dr. Michael Cho at Iowa State 
University. The title of the project is Enhancing B Cell 
Immunity Against HIV-1 Using Novel Vaccine Delivery 
Platforms. This subcontract is for the period of August 1, 
2010 through July 31, 2015. The total amount of this award 
is expected to be $525,000. 
 
Recent Publications 
Neoplastic pulmonary cytology:  why All the Fuss Over 
“NSCLS”? 
Cohen MD, Weydert JA.  Department of Pathology, 
University of Iowa Hospitals and     Clinics. 
Cancer Cytopathology 2010 Dec 23. 
 
Degrees of dysplasia and the use of cidofovir in patients 
with recurrent respiratory papillomatosis. 
Gupta HT, Robinson RA, Murray RC, Karnell LH, Smith 
RJ, Hoffman HT. 
Department of Otolaryngology, University of Iowa 
Hospitals and Clinics, Iowa City, Iowa. 
Laryngoscope. 2010 Apr;120(4):698-702. 
 
Expression profiling of transcription factors in B- or T-
acute lymphoblastic leukemia/lymphoma and burkitt 
lymphoma: usefulness of PAX5 immunostaining as pan-
Pre-B-cell marker.  
Nasr MR, Rosenthal N, Syrbu S. 
Am J Clin Pathol. 2010 Jan;133(1):41-8. 
 
Angiosarcoma following MammoSite((R)) partial breast 
irradiation. 
Andrews S, Wilcoxon R, Benda J, Jacobson G. Department 
of Radiation Oncology,   
University of Iowa Hospitals and Clinics, 200 Hawkins 
Drive, Iowa City, IA, 52242, USA. 
Breast Cancer Res Treat. 2010 May 23  
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Frequent Attenuation of the WWOX Tumor 
Suppressor in Osteosarcoma Is Associated with 
Increased Tumorigenicity and Aberrant RUNX2 
Expression. 
Kurek KC, Del Mare S, Salah Z, Abdeen S, Sadiq H, 
Lee SH, Gaudio E, Zanesi N, Jones KB, Deyoung B, 
Amir G, Gebhardt M, Warman M, Stein GS, Stein JL, 
Lian JB, Aqeilan RI. 
Cancer Res. 2010 Jun 8.  
 
Nitroxidergic innervation of human cerebral 
arteries. 
Taktakishvili OM, Lin LH, Vanderheyden AD, 
Nashelsky MB, Talman WT. 
Auton Neurosci. 2010 May  
 
Elevated oxidative membrane damage associated 
with genetic modifiers of lyst-mutant    
phenotypes. 
Trantow CM, Hedberg-Buenz A, Iwashita S, Moore SA, 
Anderson MG. 
PLoS Genet. 2010 Jul 1;6:e1001008. 
 
Dystroglycan is not required for maintenance of the 
luminal epithelial basement membrane or cell 
polarity in the mouse prostate. 
Esser AK, Cohen MB, Henry MD. 
Prostate. 2010 May 15;70(7):777-87. 
 
Commentary: Mentoring the mentor: executive 
coaching for clinical departmental executive officers. 
Geist LJ, Cohen MB. 
Acad Med. 2010 Jan;85(1):23-5. 
 
Intestinal lymphangiectasia mimicking primary 
peritoneal carcinoma. 
Steines JC, Larson JH, Wilkinson N, Kirby P, 
Goodheart MJ. 
Am J Obstet Gynecol. 2010 Oct;203(4):e9-e11. 
 
Antibody expiration in the context of resource 
limitation: what is the evidence basis? 
Savage EC, DeYoung BR. 
Am J Clin Pathol. 2010 Jul;134(1):60-4. 
 
Regulator of G protein signaling 6 (RGS6) induces 
apoptosis via a mitochondrial-dependent pathway 
not involving its GTPase-activating protein activity. 
Maity B, Yang J, Huang J, Askeland RW, Bera S, Fisher 
RA.  
J Biol Chem. 2010 Nov 1. 
 
Giant renal angiomyolipoma without fat density on 
CT scan: case report and review of the literature. 
Nepple KG, Bockholt NA, Dahmoush L, Williams RD. 
ScientificWorldJournal. 2010 Jul 7;10:1334-8.  
 
Hepatocellular carcinoma masquerading as a large 
renal mass with hepatic invasion. 
Zabell JR, Nepple KG, Wilkinson NW, Dahmoush L, 
Williams RD. 
ScientificWorldJournal. 2010 Feb 17;10:301-7. 
 
Lymphocytic esophagitis: A possible manifestation of 
pediatric upper gastrointestinal Crohn's disease. 
Ebach DR, Vanderheyden AD, Ellison JM, Jensen CS. 
Inflamm Bowel Dis. 2010 May 19 
 
Cystic fibrosis pigs develop lung disease and exhibit 
defective bacterial eradication at birth. 
Stoltz DA, Meyerholz DK, Pezzulo AA, Ramachandran 
S, Rogan MP, Davis GJ, Hanfland RA, Wohlford-
Lenane C, Dohrn CL, Bartlett JA, Nelson GA 4th, 
Chang EH, Taft PJ, Ludwig PS, Estin M, Hornick EE, 
Launspach JL, Samuel M, Rokhlina T, Karp PH, 
Ostedgaard LS, Uc A, Starner TD, Horswill AR, 
Brogden KA, Prather RS, Richter SS, Shilyansky J, 
McCray PB Jr, Zabner J, Welsh MJ. 
Sci Transl Med. 2010 Apr 28;2(29):29ra31. 
 
Mechanisms by Which Chronic Ethanol Feeding 
Limits the Ability of Dendritic Cells to Stimulate T-
Cell Proliferation. 
Fan J, Edsen-Moore MR, Turner LE, Cook RT, Legge 
KL, Waldschmidt TJ, Schlueter AJ. 
Alcohol Clin Exp Res. 2010 Oct 6. doi: 10.1111/j.1530-
0277.2010.01321.x.  
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Resident Awards 
 
The Richard G. Lynch Award for Excellence  
in Pathology 
Serena Heinz, MSTP/M1G and Desi Schoo, M2, were presented The Richard G. Lynch 
Award for Excellence in Pathology at the celebration dinner following the Medical 
Student Summer Research Day on September 10, 2010.  The Department of Pathology 
sponsors two awards in honor of Richard G. Lynch, MD, for the best poster or oral 
presentation by a medical student. The award was open to student research in any 
department in any project area. The presentations were judged by an independent panel of 
faculty judges and the awards were given to the two top scoring students. 
Serena Heinz, MSTP/M1G  
Poster:  Modification of the Immune Response to Influenza A Virus Infection by 
Prostaglandin D2  
Mentor: Dr. Kevin Legge, Pathology 
Desi Schoo, M2 
Poster:  Bcl-2 Blocks Cell Death but Increases Oxidative Stress in SOD2 Deficient 
Thymocytes.  
Mentor: Dr. C Michael Knudson, Pathology and Dr. Frederick Domann, Radiation 
Oncology
 
 
 
Desi Schoo 
 
Serena Heinz 
 
2010-2011 Co-Chief Residents 
Congratulations are extended to Benjamin Darbro, MD, PhD, and Martin Potash, MD, 
as the newly appointed 2010-2011 Co-Chief Residents.  A special thank you goes to 
Shannon Gabriel-Griggs, MD, and Megan Samuelson, MD, for serving as the 2009-2010 
Co-Chief Residents. 
Benjamin Darbro, MD, PhD 
BS Nebraska Wesleyan University, 1999 
PhD University of Iowa Roy J. and Lucille A. Carver College of Medicine, 2007 
MD University of Iowa Roy J. and Lucille A. Carver College of Medicine 
Martin Potash, MD 
BS University of Iowa, 2000 
MD University of Iowa Roy J. and Lucille A. Carver College of Medicine, 2007 
 
 
Benjamin Darbro 
 
Martin Potash 
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2010-2011  
1st Year Residents 
Michelle Kurt, MD 
BS – College of St. Benedict/St. John’s 
University, 2006 
MD – University of Iowa, Roy J. and Lucille A. 
Carver College of Medicine, 2010 
 
 
 
 
Brittany Pakalniskis, MD 
BS – The Ohio State University, 2005 
MD – Dartmouth Medical School, 2010 
 
    
 
 
 
 
Erica Savage, MD 
BA – Saint Olaf College, 2005 
MD – with Research Distinction,  
University of Iowa, Roy J. and Lucille A. 
Carver College of Medicine, 2010 
 
 
 
 
Johanna Savage, MD 
BA – Saint Olaf College, 2005 
MD – with Research Distinction,  
University of Iowa, Roy J. and Lucille A. 
Carver College of Medicine, 2010 
 
 
Bryan Steussy, MD 
BS Iowa State University, 2005 
MD with Teaching Distinction,  
University of Iowa, Roy J. and Lucille A.    
Carver College of Medicine, 2010 
 
WELCOME 
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Pathology Staff Roster  
2010-2011 
Melissa Meier, MD R4  
Joseph Mitros, MD R4  
Martin Potash, MD R4  
Rebecca Wilcoxon, MD R4 
John Blau, MD R3  
Benjamin Darbro, MD, PhD R3  
Michael Gailey, DO R3 
Brian Linert, MD R3   
Joel Miron, MD R3 
Eyglo Thordardottir, MD       R3 
Eric Hanson, MD R2 
Emilian Racila, MD R2 
Lori Sinclair, MD R2 
Thomas Wilson, MD R2 
Michelle Kurt, MD R1 
Brittany Pakalniskis, MD R1 
Erica Savage, MD R1 
Johanna Savage, MD R1 
Bryan Steussy, MD R1 
 
Pathology Externs 
2010-2011 
Lindsey Arnold  M2  
Matthew Bream  M3  
Michael Haugsdal  M2  
Natalya Hutchinson  M3 
Katherine Lynch  M2  
 
Residency Program Director  
Leslie Bruch, MD 
Associate Professor 
Pathology Fellows  
2010-2011 
Sara M. Shunkwiler, MD   
Cytopathology Fellow 
Shannon M. Gabriel-Griggs, MD 
Hematopathology Fellow 
Daniel C. Marko, BMBS   
Medical Microbiology Fellow 
Sophie Arbefeville, MD   
Molecular Genetics Pathology Fellow 
Sara “Beth” Kilborn, MD   
Surgical Pathology Fellow 
Benjamin R. Koch, MD   
Surgical Pathology Fellow 
Megan I. Samuelson, MD   
Surgical Pathology Fellow 
Links of Interests: 
Pathology Department: 
www.healthcare.uiowa.edu/pathology 
Resident & Fellow Information:  
www.healthcare.uiowa.edu/pathology/site/residents 
Laboratory Services Handbook for PDA or Pocket PC:  
www.healthcare.uiowa.edu/path_handbook/pda 
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Spring Greetings from Shelly Mott 
Department of Pathology Representative for the UI Foundation 
Although I am new to the role I play at the UI Foundation, I am certainly not new to 
the University of Iowa!  I grew up in Tipton, IA and met my husband while we were 
attending the University of Iowa back in the late 80’s.  We moved away, started a 
family and after a 15 year career in Law, and a professional football stint by my 
husband, we were thrilled for the opportunity to return to Iowa City! 
Since I started last year, I have had the privilege of visiting a few of our Pathology 
alumni and look forward to meeting many more of you.  Private support has always 
been important, but it is nothing short of critical in today’s funding environment.  
Hundreds of donors express their loyalty to the Department of Pathology through an 
annual gift.  We appreciate those who have done so, and welcome new givers to 
begin!  Other donors make larger contributions establishing an endowed fund through 
an outright gift or estate planning.  These are the gifts that make new chairs, 
professorships, scholarship and research funds available.  The Foundation has several 
endowment opportunities available that you can arrange now, with cash and 
securities, or later through a will or trust.  Estate gifts allow us to look ahead and plan 
with confidence providing financial light for future generations.  The paper work is 
minimal compared to the satisfaction you will receive. 
 
As the Department’s representative for the UI Foundation, I would love to hear your 
Iowa story and be a resource to you as you shape your philanthropic legacy.  I 
encourage you to support the Department of Pathology by giving online at 
www.medicine.uiowa.edu/pathology/.  If you have any questions, regarding giving 
opportunities or Department’s needs, feel free to contact me by sending an email to 
shelly-mott@uiowa.edu or calling (800) 648-6973.  Thank you again for your 
interests in and support of the Department of Pathology. 
 
 
Shelly J. Mott 
Associate Director of Development 
Carver College of Medicine/University of Iowa Hospitals and Clinics 
The University of Iowa Foundation 
 
Shelly Mott 
 
Private support has always 
been important, but it is nothing 
short of critical in today’s 
funding environment. 
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